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Current Landscape
of Treatments for
Wolfram Syndrome
Damien Abreu1,2
and Fumihiko Urano1,3,*
Wolfram syndrome is a rare genetic
spectrum disorder characterized by insulin-dependent diabetes mellitus, optic nerve atrophy, and progressive neurodegeneration, and ranges from mild
to severe clinical symptoms. There is
currently no treatment to delay, halt,
or reverse the progression of Wolfram
syndrome, raising the urgency for innovative therapeutics for this disease.
Here, we summarize our vision for
developing novel treatment strategies
and achieving a cure for Wolfram-syndrome-spectrum disorder.

Clinical Manifestations of
Wolfram Syndrome
Wolfram syndrome is a rare, monogenic
life-threatening disease caused largely
by mutations in the WFS1 gene or, in a
small fraction of patients, pathogenic
variants in the CISD2 gene [1]. While insulin-dependent diabetes mellitus, optic nerve atrophy, and neurodegeneration are cardinal features of this
disease, many patients also develop
other symptoms, ranging from hearing
loss and endocrine deficiencies to
neurological and psychiatric conditions
[1]. Accordingly, recent clinical and genetic findings have revealed that
Wolfram syndrome is best characterized as a spectrum disorder. Most
Wolfram syndrome patients carry two
recessive pathogenic variants in the
WFS1 gene. The disease begins to
manifest with the clinical onset of insulin-dependent diabetes mellitus at
around age 6 years and optic nerve atrophy at age 10 years. Diabetes insipidus, neurogenic bladder, obstructive

sleep apnea, and deafness may also
develop in the next two decades of
life, along with symptoms of brainstem
and cerebellar atrophy, such as
dysphagia, ataxia, and central sleep apnea [1–4]. Some pathogenic variants of
WFS1, particularly dominant variants,
cause deafness or diabetes alone [5,6].
Other dominant WFS1 variants give
rise to deafness and optic nerve atrophy or autosomal dominant congenital
cataracts [7,8]. Recently, Dr. Hattersley’s team and ours identified several
dominant de novo WFS1 variants associated with a genetic syndrome of
neonatal/infancy-onset
diabetes,
congenital sensorineural deafness, and
congenital cataracts [9]. Consequently,
WFS1 is a locus of broad interest to
various disease processes, highlighting
the need for therapeutics targeting the
gene towards potential treatments for
Wolfram-syndrome-spectrum
disorders.
Wolfram syndrome is recognized as a
prototype of endoplasmic reticulum
(ER) disorder [10]. The ER plays a critical
role in the proper folding of secretory
and membrane proteins, calcium homeostasis, and lipid biosynthesis. In
Wolfram syndrome, dysregulation of
calcium homeostasis and misfolding of
pathogenic WFS1 variants causes ER
stress in pancreatic b cells, neurons,
retinal ganglion cells and oligodendrocytes, resulting in the dysfunction and
degeneration of affected tissues. ER
dysfunction can also alter mitochondrial dynamics, thereby contributing to
neuropsychiatric aspects of this disease
[11]. Wolfram syndrome is thus a systemic disorder caused by ER dysfunction with no treatments available to
delay, halt, or reverse disease progression. Nevertheless, numerous avenues
of therapeutic development are
currently under study, heralding the
possibility of new treatments on the horizon (Figure 1). Below, we discuss the

ongoing efforts on the development
of novel treatments for Wolfram
syndrome.

Chemical Chaperones
A common molecular signature of
Wolfram syndrome is cellular stress
caused by the expression of mutant
Wolfram syndrome 1 (WFS1) proteins
derived from pathogenic WFS1 alleles.
To resolve this, we are testing chemical
chaperones that can optimize the structure of mutant WFS1 proteins. Chemical chaperones, such as 4-phenylbutyric
acid and tauroursodeoxycholic acid,
are drugs that are known to mitigate
ER stress by rescuing or stabilizing the
native conformation of mutant WFS1
proteins, thereby reducing protein aggregation and ER stress [12] (Figure 1).
Such designer chemical chaperones
hold the potential to delay Wolfram
syndrome disease progression by
reducing the misfolded WFS1 protein
load in affected cell types, thereby
salvaging remaining tissue function.

ER Calcium Stabilizers
To target calcium dyshomeostasis for
the treatment of Wolfram syndrome,
we are developing and repurposing putative ER calcium stabilizers. We
recently discovered, for example, that
dantrolene sodium, a US Food and
Drug Administration (FDA)-approved
drug for malignant hyperthermia and
muscle spasm, can act as an ER calcium
stabilizer by targeting ER calcium transporters, specifically ryanodine receptors. Dantrolene sodium can suppress
cell death and dysfunction in neuronal
and b cell mouse models of Wolfram
syndrome, as well as in induced pluripotent stem cell (iPSC) models of this disease [13] (Figure 1). These results
prompted us to initiate an ongoing
phase 1b/2 clinical trial of dantrolene
sodium to assess its safety, tolerability,
and efficacy in pediatric and adult
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trial is currently underway to evaluate
valproic acid in patients with Wolfram
syndrome (Clinical Trial Number:
NCT03717909).
Glucagon-like peptide (GLP)-1 receptor
agonists are another promising treatment for preventing ER-stress-mediated cell death in Wolfram syndrome.
It has been previously shown that GLP1 can suppress apoptosis in cell models
of Wolfram syndrome [13]. Now, data
from two rodent models of Wolfram
syndrome and one patient case report
have confirmed that GLP-1 receptor agonists may improve diabetes in
Wolfram syndrome [16,17]. Further preclinical and clinical studies are needed
to assess the broader efficacy of GLP1 agonists in patients with Wolfram
syndrome.

Potential Other Approaches

Figure 1. Current and Potential Therapeutic Strategies for Wolfram Syndrome.
Schematic shows various pathophysiological steps in development of Wolfram syndrome. The
discussed therapies are shown at the step that they target. Therapies currently in clinical trials and
being developed preclinically are in solid red and dashed blue boxes, respectively. Abbreviations:
AAV, adeno-associated virus; ER, endoplasmic reticulum; GLP-1, glucagon-like peptide 1; iPSC,
induced pluripotent stem cell; WFS1, Wolfram syndrome 1.

patients with Wolfram syndrome (Clinical Trial Number: NCT02829268i).
We are also now developing novel ER
calcium stabilizers tailored for Wolfram
together with the National Center
for Advancing Translational Sciences
(NCATS)ii. These second-generation ER
calcium stabilizers also target ER calcium
transporters, but are intended to be
safer, more potent and have greater
bioavailability to the central nervous system and eyes than dantrolene sodium.
712

Recent reports indicate that WFS1 loss
of function is associated with mitochondrial dysfunction [11,18]. This likely
stems from ER calcium leakage/ER
stress causing mitochondrial calcium
overload, which results in aberrant organellar function and decreased ATP
production. In light of these reports,
mitochondrial modulators aimed at
restoring mitochondrial function may
merit further investigation in the
context of Wolfram syndrome, as they
may be able to delay neurodegeneration by reducing neuronal dysfunction.

Targeting ER Stress
An interesting molecular target for therapeutic development is p21, which
plays a role in cell proliferation and survival after ER stress. Valproic acid, a
well-known mood stabilizer, has been
shown to increase the expression of
p21 and confer protection against cell
death in a cell of Wolfram syndrome
[14]. Valproic acid also induces WFS1
expression and modulates the ER stress
response [15]. A phase 2 double-blind,
placebo-controlled drug repurposing
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Gene Therapy
One of the approaches to provide a
cure to Wolframs syndrome could be
via gene therapy. Using adeno-associated viral (AAV) systems, wild-type
WFS1 could be transferred into the
retinal ganglion cells of patients with
Wolfram syndrome (Figure 1) to supplement the production of correct protein
in the human body. We also envision
using CRISPR/CAS9 gene editing technology for replacing pathogenic WFS1
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variants with wild-type WFS1 alleles in
Wolfram syndrome patients’ iPSCs and
then create iPSC-derived organoids to
further
determine
whether
this
approach can be used in combination
with regenerative cell-replacement efforts (discussed below).

studies will be required to optimize delivery, minimize adverse effects and
maximize therapeutic benefit.

Concluding Remarks and Future
Perspectives

Regenerative Medicine
Given the deleterious effects of chronic
ER stress on specific cell types in
Wolfram syndrome, there is a need for
regenerative medicine efforts aimed at
replacing these damaged tissues.
More specifically, there is a need for replacing pancreatic b cells and retinal
ganglion cells in patients, as defects in
these cell types have the greatest
impact on patients’ quality of life. To
this end, regenerative therapy options
using iPSCs have been developed
[19]. iPSCs from patients with Wolfram
syndrome and their respective siblings
and/or parents have been generated
[13], which could potentially be differentiated into neural progenitor cells,
retinal ganglion cells, oligodendrocytes, and pancreatic b cells for therapeutic testing and molecular investigation. These iPSC-derived cell types
may one day be used for cell-based
replacement therapy.

Wolfram syndrome is a rare genetic disorder with more than 200 pathogenic
variants reported in association with
disease. Clinical and genetic heterogeneity, as well as variable expressivity,
pose a challenge for designing effective therapies in this population.
We should therefore aim to design
personalized treatments for Wolfram
syndrome patients in the future.
The first step towards this goal is to
stratify patients based on their genetics. Genetic testing based on nextgeneration sequencing (NGS) technology, including exome and genome
sequencing, has the ability to do this
by identifying DNA variants that highly
correlate with each patient’s clinical
signs and symptoms. Routine use of
NGS-based genetic testing will not
only facilitate patient counseling by
medical geneticists and genetic counselors, but also serve as a first step towards designing personalized treatments for patients with Wolfram
syndrome.

In addition to developing cell-replacement therapeutic strategies, the regenerative properties of factors such as
mesencephalic astrocyte-derived neurotrophic factor (MANF), can be tested
on tissues especially sensitive to WFS1
loss of function. MANF has been shown
to activate proliferation of primary islets
and confer protection against ERstress-mediated cell death [20]. A therapeutic strategy could be to directly
deliver MANF to neurons, pancreatic b
cells and retinal ganglion cells via AAV
systems, with the goal of suppressing
neurodegeneration and improving b
cell mass, glucose tolerance, and visual
acuity. Further safety and efficacy

Notably, although Wolfram syndrome
is an ultra-rare genetic disorder, its constituent medical components (e.g., diabetes mellitus, deafness, and retinal
degeneration) and underlying ER pathophysiology are not as rare. Consequently, novel treatments designed for
this ultra-rare disorder may have
broader implications for more common
medical conditions related to ER stress
and dysfunction. Thus, by leveraging
the tools and therapeutic efforts targeting Wolfram syndrome, we may identify novel treatment modalities for
more prevalent disorders such as diabetes mellitus and neurodegenerative
diseases.
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Spotlight

Interleukin-13 Is
Unlucky for Allergy
Sufferers
Markus M. Xie1
and Alexander L. Dent1,*
Anaphylaxis, a life-threatening allergic
reaction, is dependent on high affinity
allergen-specific IgE. Gowthaman
et al. now show that a new interleukin
(IL)-13-expressing T helper cell subset
specifically promotes high-affinity IgE
responses. The discovery of T follicular
helper (Tfh)13 cells defines potential
new targets for allergy therapies.

The increase in atopic and allergic diseases over the past 30–40 years is of
epidemic proportions and these diseases affect millions of people in the
USA [1,2]. Allergic reactions can lead
to anaphylaxis, a severe and life-threatening form of allergic immune
response. Anaphylaxis is a systemic inflammatory response that results in a
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dramatic loss of blood pressure and
can lead to organ failure. Food allergies, especially to peanut proteins,
often involve anaphylactic reactions [3].
During the priming phase of an allergic
immune reaction, Interleukin-4 (IL-4) is
produced by T helper (Th) cells that promote the production of antigen-specific
IgE antibody from B cells. Most IgE then
binds strongly to Fcε receptors on mast
cells. IgE with low affinity for the
allergen protein is not sufficient to fully
activate mast cells and cannot provoke
anaphylaxis in the presence of allergen
(Figure 1A). However, the interaction
of allergen proteins with high-affinity
allergen-specific IgE on the mast cell
surface causes crosslinking of the Fcε
receptors, triggering a signaling
cascade that leads to mast cell degranulation and release of preformed inflammatory mediators stored in cytoplasmic granules, including histamine,
proteases, cytokines, and chemokines
(Figure 1B) [4]. Release of these inflammatory mediators in a systemic
response leads to the severe allergic reaction of anaphylaxis.
Recent studies have revealed that
specialized IL-4-secreting T follicular
helper (Tfh) cells are essential for the
development of antigen-specific IgE
from activated B cells within a cellular
structure found in lymphoid tissues
called the germinal center [5]. The discovery that Tfh cells control IgE responses has expanded our knowledge
of mechanisms that control the development of allergies. However, a crucial
aspect of the anaphylactic response is
that it is dependent on the development of high-affinity IgE specific for
the allergen [6] and despite the clinical
significance of anaphylaxis, the question of how high-affinity, allergen-specific IgE develops in the germinal center
has been unclear. Now, investigators
from Yale University and the Jackson

